Mexico Health Review 2020/21

Page 65

4

Generics Whether treating simple ailments or chronic degenerative diseases, generics companies are a significant contributor to Mexico’s healthcare industry and economy, while providing an accessible solution for patients paying out of pocket. In 2020, the generics industry experienced favorable changes regarding production. COFEPRIS eliminated criteria that limited generics manufacturing once the corresponding patent expired. Meanwhile, the new Industrial Innovation Protection Law derived from USMCA sought to speed up the entry of generics to the market by helping producers to prepare for when the patents expire. However, changes to the centralized medicine purchasing scheme and the federal medicine supply coming from UNOPS present a challenge for this industry. Overall, generics sales experienced 19.1 percent growth last year, according to ANADIM’s figures. Looking ahead, industry players are focusing on biosimilar production, opening dialogue with Mexican authorities, expansion and an overall strengthening of the industry in terms of quality and production capacity. Large multinational players are even taking a positive look at Mexico’s chemical pharmaceutical industry to exploit its manufacturing capabilities for API production. This chapter explores an important industry for the country’s micro and macro economy, with hopes for a thriving 2021.


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.